Argenx's investigational therapy, subcutaneous efgartigimod alfa, has been granted Promising Innovative Medicine (PIM) status by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). This designation signals its potential for inclusion in the UK’s Early Access to Medicines Scheme (EAMS).
David Knechtel, General Manager of argenx UK & Ireland, stated, “We welcome the MHRA’s recognition of efgartigimod alfa’s potential to address the significant unmet need in CIDP.”
CIDP is an autoimmune disorder affecting the peripheral nervous system, causing severe disability through muscle weakness and sensory issues. In the UK, it affects approximately 650 people annually and often leads to long-term disability. Current treatments are insufficient for many patients, leaving them with ongoing neurological problems.
Mechanism of Action
Efgartigimod alfa is a human antibody fragment designed to block a receptor involved in the autoimmune response, thereby reducing the harmful antibodies that attack nerve cells. It is already approved for treating generalized myasthenia gravis (gMG) and is now showing promise for CIDP.
Unmet Need in CIDP
Knechtel emphasized the urgent need for effective alternatives, given the limitations of current therapies. The new designation marks the second PIM status for efgartigimod, previously recognized for gMG treatment. CIDP patients and healthcare providers are hopeful that this innovative approach will soon provide relief where existing options fall short.
Future Directions
With ongoing research and potential EAMS inclusion, argenx aims to bring this therapy to those in need swiftly. The investigation into efgartigimod alfa’s efficacy in CIDP continues, offering hope for improved patient outcomes and quality of life. This recognition from the MHRA underscores the therapy’s promise and the need for continued innovation in treating severe autoimmune diseases.
